Abstract
We evaluated a catheter-lock solution consisting of N-acetylcysteine, tigecycline, and heparin for catheter salvage in patients with hemodialysis catheter-associated bacteremia. Eighteen case patients received the catheter-lock solution for 14 days plus systemic antibiotic therapy. Treatment was successful for 15 (83%) of the 18 case patients within 90 days of follow-up, with a median catheter retention interval of 64.5 days.
Trial registration:
ClinicalTrials.gov NCT00614679.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Acetylcysteine / administration & dosage
-
Acetylcysteine / adverse effects
-
Acetylcysteine / therapeutic use*
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / drug therapy*
-
Bacteremia / microbiology
-
Catheterization / adverse effects*
-
Female
-
Gram-Negative Bacterial Infections / drug therapy
-
Gram-Negative Bacterial Infections / microbiology
-
Gram-Positive Bacterial Infections / drug therapy
-
Gram-Positive Bacterial Infections / microbiology
-
Humans
-
Male
-
Middle Aged
-
Minocycline / administration & dosage
-
Minocycline / analogs & derivatives*
-
Minocycline / therapeutic use
-
Pilot Projects
-
Prospective Studies
-
Renal Dialysis / adverse effects*
-
Tigecycline
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Tigecycline
-
Minocycline
-
Acetylcysteine
Associated data
-
ClinicalTrials.gov/NCT00614679